Expressions of CD34, CD123 and CD38 in acute myelogenous leukemia and their clinical significances
10.3760/cma.j.issn.1009-9921.2018.10.007
- VernacularTitle:急性髓系白血病患者CD34、CD123、CD38的表达及其临床意义
- Author:
Dandan ZHAO
1
;
Hui XU
;
Han LING
;
Yahong LI
;
Yuguo KANG
;
Jianxiong PENG
Author Information
1. 山西省眼科医院检验科
- Keywords:
Leukemia;
myelogenous;
acute;
CD34;
CD123;
CD38
- From:
Journal of Leukemia & Lymphoma
2018;27(10):604-608
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expressions of CD34, CD123 and CD38 in acute myelogenous leukemia (AML) and their clinical significances. Methods A total of 164 patients with AML in Xiangya Hospital of Central South University from February 2014 to July 2015 were enrolled. Cellular immunophenotyping was performed by flow cytometry. According to the expressions of CD34, CD38 and CD123, 164 patients were divided into positive group and negative group, and the clinical data and immature cells ratio of two groups were compared. Results In 164 patients with AML, 102 cases (62.2 ％) were CD34 positive, 126 cases (76.8％) were CD123 positive, and 144 cases (88.3％) were CD38 positive. There were no significant differences in age and sex between the positive and negative groups (P> 0.05). But there were significant differences in the proportion of immature cells, white blood cell count and hemoglobin between the two groups (all P< 0.05). The expression rates of CD34, CD38 and CD123 were correlated with minimal residual disease and complete remission rate (all P< 0.05). Conclusions CD34, CD123 and CD38 are effective markers for AML detection. The expressions of CD34, CD123 and CD38 can be used as the judgment marker of cell maturity, which is conducive to the determination of the condition and prognosis of AML patients.
